NRX Pharmaceuticals Cuts Net Loss 74% to $1.4M, Secures FDA Trial Clearance
NRXP•NRX Pharmaceuticals reported a Q1 operating loss of $4.7M and a net loss of $1.4M, down 74% year-over-year, and is now debt-free after raising $7M post-quarter. The FDA cleared NRX-101 for a registrational trial and gave positive feedback on preservative-free KETAFREE, while the company plans 1–2 million unit inventory for launch.
1. Q1 Financial Results
NRX Pharmaceuticals reported a Q1 2026 operating loss of $4.7 million and net loss of $1.4 million ($0.04 per share), representing a 74% reduction year-over-year. The company exited the quarter debt-free and secured $7 million in additional capital to support ongoing operations.
2. FDA Regulatory Updates
NRX-101 has received FDA clearance to enter a registrational trial, with the MIND1 trial positioned to tap non-dilutive federal funding. The preservative-free KETAFREE formulation earned positive FDA feedback, requiring only minor administrative adjustments before approval.
3. Commercial and Manufacturing Outlook
KETAFREE will be distributed through existing hospital channels and directly to clinics to replace compounded products. Management plans to hold 1 to 2 million units at launch and leverage high-volume manufacturing capabilities to address the ketamine shortage.
